Why would anyone expect the SP to increase significantly on this ann? It is dosing a first patient. It’s a great box to tick but that’s all it is.
As others have said, the only things that will get us moving are further great trial results, a b-cell platform deal (which should put a higher floor under the SP before the main event(s) or some commercial partnership deal with BP to fund future trials etc.
Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient, page-83
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.001(6.67%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.3¢ | $255.7K | 18.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 65 | 18692454 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 4515891 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |